[乳腺癌生物标志物评估的分析前阶段：2014年法国GEFPICS指南更新]
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France].
作者信息
MacGrogan Gaëtan, Mathieu Marie-Christine, Poulet Bruno, Penault-Llorca Frédérique, Vincent-Salomon Anne, Roger Pascal, Treilleux Isabelle, Valent Alexander, Antoine Martine, Becette Véronique, Bor Catherine, Brabencova Eva, Charafe-Jauffret Emmanuelle, Chenard Marie-Pierre, Dauplat Marie-Mélanie, Delrée Paul, Devouassoux Mojgan, Fiche Maryse, Fondrevelle Marie-Eve, Fridman Viviana, Garbar Christian, Genin Pascal, Ghnassia Jean-Pierre, Haudebourg Juliette, Laberge-Le Couteulx Sophie, Loussouarn Delphine, Maran-Gonzalez Aurélie, Marcy Myriam, Michenet Patrick, Sagan Christine, Trassard Martine, Verriele Véronique, Arnould Laurent, Lacroix-Triki Magali
机构信息
Groupe d'étude des facteurs pronostiques immunohistochimiques dans le cancer du sein, Unicancer, 101, rue de Tolbiac, 75654 Paris cedex 13, France.
Groupe d'étude des facteurs pronostiques immunohistochimiques dans le cancer du sein, Unicancer, 101, rue de Tolbiac, 75654 Paris cedex 13, France.
出版信息
Ann Pathol. 2014 Oct;34(5):366-72. doi: 10.1016/j.annpat.2014.08.017. Epub 2014 Sep 26.
Biomarker assessment of breast cancer tumor samples is part of the routine workflow of pathology laboratories. International guidelines have recently been updated, with special regards to the pre-analytical steps that are critical for the quality of immunohistochemical and in situ hybridization procedures, whatever the biomarker analyzed. Fixation and specimen handling protocols must be standardized, validated and carefully tracked. Cooperation and training of the personnel involved in the specimen workflow (e.g. radiologists, surgeons, nurses, technicians and pathologists) are of paramount importance. The GEFPICS' update of the recommendations herein details and comments the different steps of the pre-analytical process. Application of these guidelines and participation to quality insurance programs are mandatory to ensure the correct evaluation of oncotheranostic biomarkers.
乳腺癌肿瘤样本的生物标志物评估是病理实验室常规工作流程的一部分。国际指南最近已更新，特别关注对免疫组织化学和原位杂交程序质量至关重要的分析前步骤，无论分析何种生物标志物。固定和标本处理方案必须标准化、验证并仔细跟踪。参与标本工作流程的人员（如放射科医生、外科医生、护士、技术人员和病理学家）的合作与培训至关重要。GEFPICS对本建议的更新详细阐述并评论了分析前过程的不同步骤。应用这些指南并参与质量保证计划对于确保正确评估肿瘤诊疗生物标志物是必不可少的。
Zotero 插件